Australian (ASX) Stock Market Forum

SPL - Starpharma Holdings

Jump to new
Knobby22 said:
Results look very good. How soon can they sell it?
Market likes it.
Click to expand...
some significant factors in favour a greatly reduced time line are mentioned in the announcement including;

SPL7013 is the active ingredient in marketed VivaGel® products and has been shown to be safe and well tolerated in multiple large international clinical trials. VivaGel® products are approved and marketed in the UK, Europe, Asia, Canada, Australia, and New Zealand, and are already manufactured at industrial scale. SPL7013 active is already scaled up for commercial supply, and the availability of existing stocks of SPL7013 will further expedite development and commercialisation of the nasal spray product.

Starpharma has undertaken extensive development activities for the SPL7013 nasal spray. To date, SPL7013 has been reformulated into several nasal spray formulations, the company has identified a manufacturer and device components, undertaken pilot manufacture, and compiled regulatory documentation in preparation for submission.

Since the world is screaming for some headway in battling the virus hopefully a successful approval and marketing process is rapid.
 
Knobby22 said:
Breakout? Finally starting to get noticed!
Will know for sure if one of the traders on the site starts buying.
Click to expand...

Yep it went very well today too. Up 25% earlier. Finishing around 18%,
Good to see they are looking at another string to the bow regarding COVID-19.
Also that the administration of the remdevisir drug is far more efficient and can be performed outside of hospitalisation.
https://www.asx.com.au/asxpdf/20200901/pdf/44m691fdmk053z.pdf
 
This should excite the market... from their announcement this morning.

 New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19
 Potent antiviral activity of SPL7013 against SARS-CoV-2 was evident when used either before or after exposure of cells to the virus meaning that the nasal spray could be used before or after exposure to the virus
 Starpharma is rapidly advancing development, regulatory, manufacturing and commercialisation activities and leveraging its extensive technical data set and approved status of SPL7013 to expedite approval with product now expected to be ready for market 1H CY2021

 
jbocker said:
This should excite the market... from their announcement this morning.

 New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19
 Potent antiviral activity of SPL7013 against SARS-CoV-2 was evident when used either before or after exposure of cells to the virus meaning that the nasal spray could be used before or after exposure to the virus
 Starpharma is rapidly advancing development, regulatory, manufacturing and commercialisation activities and leveraging its extensive technical data set and approved status of SPL7013 to expedite approval with product now expected to be ready for market 1H CY2021

Click to expand...
Getting excited and feeling wealthy!! I don't know why I didn't pick this as my monthly tip.
Where are the traders?
 
Last edited:
I was wondering why I didnt either.:D
What is impressive is the results were achieved by Scripps Research Institute...
Scripps Research Institute is ranked the most influential institution in the world for its impact on innovation. Scripps’ researchers lead breakthrough studies that address the world’s most pressing health concerns. In 2018, Scripps Research was ranked top stand-alone scientific institute in the United States for producing high-quality research by Nature Index, based on discoveries published in leading scientific journals.
 
jbocker said:
Trading Halt for capital raise? Got $30M in the bank picked up $1M grant, potential milestone payments, $7M earnings (potentially increasing) against $14M burn (loss).
Any thoughts on why the capital raising. It is a tough time to raise $.
Interested in thoughts.
Click to expand...

They don't need the money.
My guess is it is to get certain US investors on board so approval can take place. Bit like MSB. Not saying the USA is not free trade but you know....it's an offer they can't refuse. At least they are having an SPP.
 
I think it got a mention on the 7 morning show, couldnt quite catch it ...noisy parents :mad: . Trying to look it up.
 
jbocker said:
I think it got a mention on the 7 morning show, couldnt quite catch it ...noisy parents :mad: . Trying to look it up.
Click to expand...

Oversubscribed at $1.50
You can bet the SPP will be oversubscribed, presently rounding up all spare cash as I am sure it will be scaled down considerably.
 
The oversubscribed placement saw a high level of demand from offshore funds including large global and US-based funds.
 
Austwide said:
Can buy now at market for $1.50
Click to expand...
sold today for a slight profit(was to be sold earlier but got into trading halt) but unhealthy to see reaching SPP price that soon..
hopefully will get some cheap entries for a quick SPP buy and sold
 
SPP Offer closes tomorrow, but I topped up what I needed at a cheaper price. Surprised there is no new 'exciting news' released to get more funds. But they are already cashed up.
 
Been away for a few days and noticed that their Viraleze announcement. I sense this will be very attractive preventative measure particularly those who would rather an alternative to the vaccine. Additionally the it is also effective against other viruses, which I dont think is the case with the vaccine.

Disclosure: Happy to be holding.


From their website. VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21 - Starpharma

Dec 10, 2020
VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21
VIRALEZE.png

  • EU regulatory dossier >90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021, earlier than previously announced
  • Initial launch batches of VIRALEZE™ scheduled for manufacture in January 2021; Starpharma is also building inventory of components and raw material to support rapid roll-out
  • Launch and marketing preparations well advanced, including discussions with pharmacy chains, B2B customers, qualitative and quantitative consumer market research; partnering discussions are continuing in parallel
  • VIRALEZE™ clinical study in healthy volunteers to commence in January 2021, for completion in Q1 CY2021
  • SPL7013 has been shown to be virucidal, inactivating more than 99.99% of SARS-CoV-2 and Scripps Research Institute mechanistic studies have confirmed potent inhibition of viral ‘spike protein’ binding (>90%)
  • The broad spectrum antiviral activity of VIRALEZE™ is a compelling differentiating feature and Starpharma is continuing to build additional efficacy data in other respiratory viruses to further broaden the product claims for VIRALEZE™
 
I am backing SPL as my top pick in the 2021 tipping competition. Tipping Competition for Full CY 2021 | Aussie Stock Forums
My opinion only.
Viraleze to be the go to product in 2021.
Being a nasal spray people will have their own.
It will be a great preventative not only for covid but also a number of other life threatening viruses.
If the flue jabs prove ineffective or unpopular then there may be a greater drive to viraleze.
Due to the above greater awareness of the dendrimer technology in cancer drug delivery will be achieved.
 

Similar threads

System
TRP - Tissue Repair
Replies
3
Views
1K
Dona Ferentes
Dona Ferentes
M
IMMU - Immunicum AB (NASDAQ)
Replies
19
Views
7K
maquet
M
shares
MCM - MC Mining
2 3 4
Replies
67
Views
25K
Dona Ferentes
Dona Ferentes
Gurgler
CYT - Cytopia Limited
Replies
1
Views
4K
moneymajix
moneymajix
O
INEX Pharmaceuticals: Great licensing agreement with Hana Biosciences
Replies
3
Views
5K
ollinbg
O
Top